Symbols / SRRK Stock $49.19 +1.74% Scholar Rock Holding Corporation

Healthcare • Biotechnology • United States • NMS
SRRK (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. David L. Hallal
Exch · Country NMS · United States
Market Cap 5.89B
Enterprise Value 5.62B
Income -408.73M
Sales —
FCF (ttm) -171.93M
Book/sh 2.26
Cash/sh 4.00
Employees 289
Insider 10d —
IPO May 25, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -21.72
PEG —
P/S —
P/B 21.74
P/C —
EV/EBITDA -13.78
EV/Sales —
Quick Ratio 8.41
Current Ratio 8.64
Debt/Eq 74.52
LT Debt/Eq —
EPS (ttm) -3.45
EPS next Y -2.26
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -54.30%
ROE -138.94%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 119.83M
Shs Float 100.84M
Insider Own 0.86%
Instit Own 106.50%
Short Float 15.68%
Short Ratio 9.22
Short Interest 14.91M
52W High 51.62
vs 52W High -4.72%
52W Low 27.07
vs 52W Low 81.71%
Beta 0.71
Impl. Vol. 73.05%
Rel Volume 0.88
Avg Volume 1.47M
Volume 1.30M
Target (mean) $59.00
Tgt Median $58.00
Tgt Low $48.00
Tgt High $70.00
# Analysts 16
Recom Strong_buy
Prev Close $48.35
Price $49.19
Change 1.74%
About

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$59.00
Mean price target
2. Current target
$49.19
Latest analyst target
3. DCF / Fair value
$-25.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$49.19
Low
$48.00
High
$70.00
Mean
$59.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-08 main Barclays Overweight → Overweight $55
2026-05-08 main HC Wainwright & Co. Buy → Buy $65
2026-04-21 init Canaccord Genuity — → Buy $62
2026-04-01 main Wedbush Outperform → Outperform $58
2026-03-16 main JP Morgan Overweight → Overweight $50
2026-03-04 main Citigroup Buy → Buy $58
2026-03-04 main BMO Capital Outperform → Outperform $70
2026-03-04 main Truist Securities Buy → Buy $55
2026-03-04 main Barclays Overweight → Overweight $53
2026-03-04 main Piper Sandler Overweight → Overweight $58
2026-03-03 reit HC Wainwright & Co. Buy → Buy $58
2026-01-26 main HC Wainwright & Co. Buy → Buy $58
2026-01-09 init Citigroup — → Buy $55
2026-01-07 init UBS — → Buy $60
2025-12-17 main Barclays Overweight → Overweight $52
2025-11-18 init Wolfe Research — → Outperform $42
2025-11-18 main JP Morgan Overweight → Overweight $47
2025-11-17 main Barclays Overweight → Overweight $45
2025-10-20 main Truist Securities Buy → Buy $44
2025-10-09 init B of A Securities — → Buy $53
News
RSS: Latest SRRK news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-23 BUROW KRISTINA M Director — 89,800 $4.75 $820,324
2026-04-16 HALLAL DAVID L Chief Executive Officer — 30,615 $49.57 $1,517,723
2026-04-16 VAISHNAW AKSHAY K Officer and Director — 12,246 $49.57 $607,089
2026-04-16 WOODS KEITH Chief Operating Officer — 10,220 $49.57 $506,651
2026-04-16 SINHA VIKAS Chief Financial Officer — 10,410 $49.57 $516,071
2026-02-23 QATANANI MOHAMMED Officer — 8,484 $46.94 $399,351
2026-02-17 MARANTZ JING L. Officer — 4,157 $46.53 $193,418
2026-02-17 HO JUNLIN General Counsel — 9,580 $46.53 $445,740
2026-02-17 PARLAVECCHIO CARYN Officer — 9,035 $46.53 $420,382
2026-02-17 QATANANI MOHAMMED Officer — 7,989 $46.53 $371,714
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
33.19
Operating Revenue
0.00
0.00
0.00
-100.00%
33.19
Operating Expense
384.64
+52.60%
252.05
+47.15%
171.29
+2.23%
167.56
Research And Development
208.44
+12.95%
184.55
+51.39%
121.90
-2.04%
124.44
Selling General And Administration
176.21
+161.03%
67.50
+36.66%
49.40
+14.56%
43.12
General And Administrative Expense
176.21
+161.03%
67.50
+36.66%
49.40
+14.56%
43.12
Other Gand A
176.21
+161.03%
67.50
+36.66%
49.40
+14.56%
43.12
Total Expenses
384.64
+52.60%
252.05
+47.15%
171.29
+2.23%
167.56
Operating Income
-384.64
-52.60%
-252.05
-47.15%
-171.29
-27.48%
-134.37
Total Operating Income As Reported
-384.64
-52.60%
-252.05
-47.15%
-171.29
-27.48%
-134.37
EBITDA
-369.39
-55.52%
-237.52
-41.00%
-168.45
-28.21%
-131.38
Normalized EBITDA
-369.39
-55.52%
-237.52
-41.00%
-168.45
-28.21%
-131.38
Reconciled Depreciation
1.66
-14.40%
1.94
-31.89%
2.84
-4.76%
2.99
EBIT
-371.05
-54.95%
-239.46
-39.79%
-171.29
-27.48%
-134.37
Net Income
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Pretax Income
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Net Non Operating Interest Income Expense
7.01
+19.88%
5.84
—
—
Interest Expense Non Operating
6.89
+0.82%
6.84
—
—
Net Interest Income
7.01
+19.88%
5.84
—
—
Interest Expense
6.89
+0.82%
6.84
—
—
Interest Income Non Operating
13.90
+9.60%
12.68
—
—
Interest Income
13.90
+9.60%
12.68
—
—
Other Income Expense
-0.30
-254.12%
-0.09
-101.54%
5.51
+4271.21%
-0.13
Other Non Operating Income Expenses
-0.30
-254.12%
-0.09
-101.54%
5.51
+4271.21%
-0.13
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Net Income From Continuing Operation Net Minority Interest
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Net Income From Continuing And Discontinued Operation
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Net Income Continuous Operations
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Normalized Income
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Net Income Common Stockholders
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Diluted EPS
-3.29
-33.20%
-2.47
-24.12%
-1.99
+11.95%
-2.26
Basic EPS
-3.29
-33.20%
-2.47
-24.12%
-1.99
+11.95%
-2.26
Basic Average Shares
114.70
+14.89%
99.84
+19.79%
83.35
+39.82%
59.61
Diluted Average Shares
114.70
+14.89%
99.84
+19.79%
83.35
+39.82%
59.61
Diluted NI Availto Com Stockholders
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
404.27
-14.88%
474.92
+52.69%
311.04
-13.16%
358.17
Current Assets
385.15
-14.63%
451.17
+56.55%
288.19
-12.14%
328.02
Cash Cash Equivalents And Short Term Investments
367.56
-15.94%
437.28
+56.21%
279.94
-11.23%
315.36
Cash And Cash Equivalents
323.53
+81.88%
177.88
+74.64%
101.86
-1.37%
103.28
Other Short Term Investments
44.04
-83.02%
259.40
+45.66%
178.08
-16.03%
212.09
Receivables
2.80
+30.13%
2.15
+99.91%
1.08
-60.66%
2.73
Other Receivables
2.80
+30.13%
2.15
+99.91%
1.08
-60.66%
2.73
Prepaid Assets
14.79
+25.98%
11.74
+63.45%
7.18
-27.68%
9.93
Other Current Assets
—
—
—
12.66
Total Non Current Assets
19.12
-19.50%
23.76
+4.01%
22.84
-24.23%
30.14
Net PPE
12.09
-34.33%
18.41
+14.91%
16.02
-38.22%
25.93
Gross PPE
26.96
-14.74%
31.62
+15.65%
27.34
-24.38%
36.16
Accumulated Depreciation
-14.88
-12.54%
-13.22
-16.70%
-11.33
-10.70%
-10.23
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.27
+10.38%
2.06
-0.67%
2.08
-3.80%
2.16
Construction In Progress
0.03
0.00
—
0.00
Other Properties
21.04
-18.93%
25.95
+19.65%
21.69
-24.80%
28.84
Leases
3.63
+0.36%
3.61
+0.89%
3.58
-30.60%
5.16
Goodwill And Other Intangible Assets
—
2.40
-41.21%
4.07
—
Other Intangible Assets
—
2.40
-41.21%
4.07
—
Non Current Prepaid Assets
3.23
+9.71%
2.94
-33.33%
4.42
—
Other Non Current Assets
3.81
+58.16%
2.41
+0.00%
2.41
-42.92%
4.22
Total Liabilities Net Minority Interest
158.78
+49.39%
106.29
+23.85%
85.82
-12.37%
97.93
Current Liabilities
55.42
+18.07%
46.94
+43.36%
32.74
-10.03%
36.39
Payables And Accrued Expenses
49.87
+21.15%
41.16
+72.13%
23.91
-15.54%
28.32
Payables
10.30
+2.06%
10.10
+191.34%
3.46
-13.24%
3.99
Accounts Payable
10.30
+2.06%
10.10
+191.34%
3.46
-13.24%
3.99
Other Payable
—
—
—
—
Current Accrued Expenses
39.57
+27.36%
31.07
+51.92%
20.45
-15.92%
24.32
Current Debt And Capital Lease Obligation
5.55
-3.88%
5.77
-33.95%
8.74
+11.33%
7.85
Current Debt
—
—
1.33
—
Other Current Borrowings
—
—
1.33
—
Current Capital Lease Obligation
5.55
-3.88%
5.77
-22.06%
7.41
-5.65%
7.85
Current Deferred Liabilities
—
—
—
0.00
Current Deferred Revenue
—
—
—
0.00
Other Current Liabilities
—
—
0.09
-61.71%
0.22
Total Non Current Liabilities Net Minority Interest
103.36
+74.16%
59.35
+11.82%
53.08
-13.76%
61.54
Long Term Debt And Capital Lease Obligation
103.36
+74.16%
59.35
+11.82%
53.08
-13.76%
61.54
Long Term Debt
99.71
+98.84%
50.15
+3.00%
48.68
-2.13%
49.74
Long Term Capital Lease Obligation
3.66
-60.29%
9.21
+109.61%
4.39
-62.78%
11.80
Stockholders Equity
245.49
-33.41%
368.63
+63.68%
225.22
-13.46%
260.24
Common Stock Equity
245.49
-33.41%
368.63
+63.68%
225.22
-13.46%
260.24
Capital Stock
0.11
+14.89%
0.09
+23.68%
0.08
+46.15%
0.05
Common Stock
0.11
+14.89%
0.09
+23.68%
0.08
+46.15%
0.05
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
108.46
+15.60%
93.82
+23.49%
75.98
+47.04%
51.67
Ordinary Shares Number
108.46
+15.60%
93.82
+23.49%
75.98
+47.04%
51.67
Additional Paid In Capital
1,545.94
+19.74%
1,291.10
+43.22%
901.47
+16.82%
771.70
Retained Earnings
-1,300.65
-40.96%
-922.72
-36.41%
-676.42
-32.47%
-510.63
Gains Losses Not Affecting Retained Earnings
0.09
-41.25%
0.16
+73.91%
0.09
+110.41%
-0.88
Other Equity Adjustments
0.09
-41.25%
0.16
+73.91%
0.09
+110.41%
-0.88
Total Equity Gross Minority Interest
245.49
-33.41%
368.63
+63.68%
225.22
-13.46%
260.24
Total Capitalization
345.20
-17.57%
418.78
+52.89%
273.90
-11.64%
309.98
Working Capital
329.73
-18.43%
404.23
+58.24%
255.45
-12.41%
291.63
Invested Capital
345.20
-17.57%
418.78
+52.15%
275.24
-11.21%
309.98
Total Debt
108.92
+67.24%
65.13
+5.35%
61.82
-10.92%
69.40
Capital Lease Obligations
9.21
-38.54%
14.98
+26.95%
11.80
-39.96%
19.65
Net Tangible Assets
245.49
-33.41%
368.63
+63.68%
225.22
-13.46%
260.24
Tangible Book Value
245.49
-33.41%
368.63
+63.68%
225.22
-13.46%
260.24
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-300.04
-49.31%
-200.95
-38.37%
-145.23
-9.44%
-132.69
Cash Flow From Continuing Operating Activities
-300.04
-49.31%
-200.95
-38.37%
-145.23
-9.44%
-132.69
Net Income From Continuing Operations
-377.94
-53.45%
-246.29
-48.56%
-165.79
-23.26%
-134.50
Depreciation Amortization Depletion
1.66
-14.40%
1.94
-31.89%
2.84
-4.76%
2.99
Depreciation And Amortization
1.66
-14.40%
1.94
-31.89%
2.84
-4.76%
2.99
Other Non Cash Items
5.68
+3.80%
5.48
-25.99%
7.40
-2.87%
7.62
Stock Based Compensation
75.60
+106.40%
36.63
+34.95%
27.14
-2.02%
27.70
Operating Gains Losses
—
—
0.01
-66.67%
0.03
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.01
-66.67%
0.03
Change In Working Capital
-1.05
-115.92%
6.59
+162.13%
-10.61
+69.14%
-34.39
Change In Receivables
—
—
—
—
Changes In Account Receivables
—
—
—
—
Change In Prepaid Assets
-3.70
+35.93%
-5.77
-227.37%
4.53
+1506.83%
-0.32
Change In Payables And Accrued Expense
8.71
-49.27%
17.16
+485.17%
-4.46
-167.13%
6.64
Change In Accrued Expense
8.50
-19.31%
10.53
+368.22%
-3.93
-157.00%
6.89
Change In Payable
0.21
-96.86%
6.63
+1353.31%
-0.53
-110.76%
-0.25
Change In Account Payable
0.21
-96.86%
6.63
+1353.31%
-0.53
-110.76%
-0.25
Change In Other Working Capital
—
—
—
-33.19
Change In Other Current Assets
-0.29
-119.43%
1.47
+154.56%
-2.70
-2681.44%
-0.10
Change In Other Current Liabilities
-5.77
+7.93%
-6.27
+21.51%
-7.99
-7.75%
-7.42
Investing Cash Flow
218.69
+387.53%
-76.06
-284.87%
41.14
+123.96%
-171.70
Cash Flow From Continuing Investing Activities
218.69
+387.53%
-76.06
-284.87%
41.14
+123.96%
-171.70
Net PPE Purchase And Sale
-0.60
-514.29%
-0.10
-68.97%
-0.06
+94.55%
-1.06
Purchase Of PPE
-0.60
-514.29%
-0.10
-38.03%
-0.07
+93.33%
-1.06
Sale Of PPE
—
0.00
-100.00%
0.01
0.00
Capital Expenditure
-0.60
-514.29%
-0.10
-38.03%
-0.07
+93.33%
-1.06
Net Investment Purchase And Sale
219.29
+388.70%
-75.96
-284.37%
41.20
+124.14%
-170.63
Purchase Of Investment
-98.01
+66.57%
-293.16
-0.81%
-290.80
+3.27%
-300.63
Sale Of Investment
317.30
+46.09%
217.20
-34.58%
332.00
+155.38%
130.00
Financing Cash Flow
228.40
-35.30%
353.03
+244.17%
102.57
-47.35%
194.83
Cash Flow From Continuing Financing Activities
228.40
-35.30%
353.03
+244.17%
102.57
-47.35%
194.83
Net Issuance Payments Of Debt
49.14
0.00
0.00
0.00
Issuance Of Debt
74.66
0.00
—
0.00
Repayment Of Debt
-25.52
0.00
0.00
+100.00%
-0.97
Long Term Debt Issuance
74.66
0.00
—
0.00
Long Term Debt Payments
-25.52
0.00
0.00
+100.00%
-0.97
Net Long Term Debt Issuance
49.14
0.00
0.00
0.00
Net Common Stock Issuance
91.66
-71.75%
324.41
+232.02%
97.71
-49.97%
195.31
Proceeds From Stock Option Exercised
87.60
+204.81%
28.74
+491.09%
4.86
+888.21%
0.49
Net Other Financing Charges
—
-0.12
-4266.67%
0.00
+100.31%
-0.97
Changes In Cash
147.05
+93.43%
76.02
+5131.30%
-1.51
+98.62%
-109.56
Effect Of Exchange Rate Changes
-0.00
0.00
—
—
Beginning Cash Position
180.28
+72.92%
104.26
-1.43%
105.77
-50.88%
215.33
End Cash Position
327.33
+81.56%
180.28
+72.92%
104.26
-1.43%
105.77
Free Cash Flow
-300.64
-49.54%
-201.05
-38.37%
-145.30
-8.63%
-133.76
Interest Paid Supplemental Data
6.07
-8.33%
6.62
+3.41%
6.40
+46.36%
4.37
Amortization Of Securities
-3.99
+24.61%
-5.29
+14.94%
-6.22
-190.38%
-2.14
Common Stock Issuance
91.66
-71.75%
324.41
+232.02%
97.71
-49.97%
195.31
Issuance Of Capital Stock
91.66
-71.75%
324.41
+232.02%
97.71
-49.97%
195.31
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category